Expert Review of Anticancer Therapy最新文献_第9页

Prognostic significance of Dickkopf-1 in head and neck squamous cell carcinoma. Dickkopf-1在头颈部鳞状细胞癌中的预后意义。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-03-01 Epub Date: 2023-12-05 DOI: 10.1080/14737140.2023.2289597

Kai Chen, Jin Li, Yanfeng Ouyang, Yulong Xie, Guiqiong Xu, Tianliang Xia, Rui You, Guichao Liu, Han He, Rong Huang, Mingyuan Chen

{"title":"Prognostic significance of Dickkopf-1 in head and neck squamous cell carcinoma.","authors":"Kai Chen, Jin Li, Yanfeng Ouyang, Yulong Xie, Guiqiong Xu, Tianliang Xia, Rui You, Guichao Liu, Han He, Rong Huang, Mingyuan Chen","doi":"10.1080/14737140.2023.2289597","DOIUrl":"10.1080/14737140.2023.2289597","url":null,"abstract":"Background: Dickkopf-1 (DKK1) exhibits abnormal expression in various cancers and correlates with poor prognosis. This study investigates DKK1's prognostic relevance in head and neck squamous cell carcinoma (HNSC).Methods: We conducted a comprehensive search across literature and sequencing databases to gather eligible studies and HNSC datasets. We calculated pooled standardized mean differences (SMD) and 95% confidence intervals (CI) for clinical characteristics, as well as hazard ratios (HR) with 95% CIs for overall survival (OS) and progression-free/disease-free survival (PFS/DFS). Sensitivity analysis gauged result stability, and Egger's test assessed publication bias.Results: Pooled results indicated that HNSC patients with higher T-stage exhibited elevated DKK1 expression levels, and this elevated expression was associated with shorter OS and PFS/DFS. While sensitivity analysis identified some studies significantly affecting pooled results, most were unaffected, and no publication bias was detected.Conclusion: DKK1 holds promise as a potential biomarker for predicting poor prognosis in HNSC patients, but further research is needed for confirmation.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing. 通过数字液滴聚合酶链反应 ddPCR 和新一代测序技术检测第三代表皮生长因子受体酪氨酸激酶抑制剂对不同 T790M 状态的晚期 NSCLC 的疗效。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-03-01 Epub Date: 2024-04-17 DOI: 10.1080/14737140.2024.2334807

Ziyi Xu, Yan Li, Lin Wang, Xuezhi Hao, Jianming Ying, Junling Li, Puyuan Xing

{"title":"Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.","authors":"Ziyi Xu, Yan Li, Lin Wang, Xuezhi Hao, Jianming Ying, Junling Li, Puyuan Xing","doi":"10.1080/14737140.2024.2334807","DOIUrl":"10.1080/14737140.2024.2334807","url":null,"abstract":"Objectives: We hypothesize that digital droplet polymerase chain reaction (ddPCR) would optimize the treatment strategies in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) relapsed patients. In this study, we compared the efficacy of third-generation TKIs with various T790M statuses via ddPCR and next-generation sequencing (NGS).Methods: NGS was performed on blood samples of patients progressed from previous EGFR-TKIs for resistance mechanism. T790M-negative patients received further liquid biopsy using ddPCR for T790M detection.Results: A cohort of 40 patients were enrolled, with 30.0% (12/40) T790M-positive via NGS (Group A). In another 28 T790M-negative patients by NGS, 11 (39.3%) were T790M-positive (Group B) and 17 (60.7%) were T790M-negative (Group C) via ddPCR. A relatively longer progression-free survival (PFS) was observed in group A (NR) and group B (10.0 months, 95% CI 7.040-12.889) than in group C (7.0 months, 95% CI 0.000-15.219), with no significant difference across all three groups (p = 0.196), or between group B and C (p = 0.412). EGFR-sensitive mutation correlated with inferior PFS (p = 0.041) and ORR (p = 0.326), and a significantly lower DCR (p = 0.033) in T790M-negative patients via NGS (n = 28).Conclusion: This study indicates that ddPCR may contribute as a supplement to NGS in liquid biopsies for T790M detection in EGFR-TKIs relapsed patients and help to optimize the treatment strategies, especially for those without coexistence of EGFR-sensitive mutation.Trial registration: www.clinicaltrials.gov identifier is NCT05458726.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity. 在 RAS 突变癌症中利用 c-RAF 依赖性：超越催化活性。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-03-01 Epub Date: 2024-02-26 DOI: 10.1080/14737140.2024.2319035

Sean F Cooke, Connor M Blair

引用次数: 0

Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer 通过免疫细胞死亡相关基因表达特征识别结直肠癌分子亚型并进行预后分层

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-02-26 DOI: 10.1080/14737140.2024.2320187

Junping Lei, Jia Fu, Tianyang Wang, Yu Guo, Mingmin Gong, Tian Xia, Song Shang, Yan Xu, Ling Cheng, Binghu Lin

引用次数: 0

Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials. Rucaparib治疗卵巢癌和BRCA基因突变患者的安全性和有效性：III期随机临床试验的系统回顾和荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-01-01 Epub Date: 2024-02-12 DOI: 10.1080/14737140.2024.2309177

Mus'ab Theeb Mustafa, Aws Khalid Abushanab, Mahmoud Taysir Mousa, Rana Ahmed Qawaqzeh, Hamza Muneer Alakhras, Ahmad Sami Othman, Ahmad Sa'ed

{"title":"Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials.","authors":"Mus'ab Theeb Mustafa, Aws Khalid Abushanab, Mahmoud Taysir Mousa, Rana Ahmed Qawaqzeh, Hamza Muneer Alakhras, Ahmad Sami Othman, Ahmad Sa'ed","doi":"10.1080/14737140.2024.2309177","DOIUrl":"10.1080/14737140.2024.2309177","url":null,"abstract":"Introduction: Our systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of Rucaparib, a PARP inhibitor (PARPi), in patients with ovarian cancer and BRCA mutation.Methods: Online databases were comprehensively searched for all phase III Randomized trials that used Rucaparib therapy for ovarian cancer patients and patients having BRCA mutation. Efficacy results are progression-free survival and overall response rate in addition to addressing its safety concerns.Results: After pooling data from 4 clinical trials, the analysis showed a significant improvement in PFS among ovarian cancer patients and for the maintenance therapy with a hazard ratio (HR) of 0.49 (95% CI 0.34-0.73, p = 0.0003) and 0.42 (95% CI 0.29-0.62, p < 0.0001), respectively. For patients with BRCA mutations, the PFS showed significant improvement with a (HR) of 0.42 (95% CI 0.25-0.71, p < 0.001). A difference was observed in the risk of grade ≥ 3 TEAEs between the two groups (RR = 2.48; 95% CI 1.40-4.37).Conclusion: Rucaparib demonstrated significant efficacy in improving PFS and ORR in ovarian cancer patients, particularly those having BRCA mutations. However, they should be closely monitored due to the greater risk of various adverse effects.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma. 皮肤 T 细胞淋巴瘤的异体移植和细胞疗法。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-01-01 Epub Date: 2024-02-12 DOI: 10.1080/14737140.2024.2305356

Amrita Goyal, Francine Foss

{"title":"Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma.","authors":"Amrita Goyal, Francine Foss","doi":"10.1080/14737140.2024.2305356","DOIUrl":"10.1080/14737140.2024.2305356","url":null,"abstract":"Introduction: Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell lymphoma. Although many available treatments offer temporary disease control, allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only curative treatment option for advanced stage MF and SS. CAR T-cell therapy is a promising new avenue for treatment.Areas covered: In this review, we discuss the evidence supporting the use of allo-HSCT for the treatment of MF/SS, including disease status at the time of transplant, conditioning regimen, total body irradiation (TBI), and donor lymphocyte infusion (DLI). We also address the potential role for CAR T-cell therapy in CTCL.Expert opinion: Allo-HSCT is an effective treatment for patients with advanced MF and SS. However, significant research is required to determine optimal treatment protocols. Data support the use of reduced-intensity conditioning regimens and suggests that the use of TBI for debulking of skin disease may result in more durable remissions. Donor lymphocyte infusions (DLI) appear to be particularly effective in inducing complete remission in MF/SS patients with relapsed or residual disease. Challenges with CAR-T therapies in T-cell lymphoma include T-cell fratricide due to shared antigens on malignant and nonmalignant T-cells, penetrance into the skin compartment, and CAR-T cell persistence.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime? NECTIN-4靶向治疗尿路上皮癌:准备好了吗?

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-01-01 Epub Date: 2024-02-12 DOI: 10.1080/14737140.2023.2288140

Luca Filippi, Orazio Schillaci

{"title":"NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?","authors":"Luca Filippi, Orazio Schillaci","doi":"10.1080/14737140.2023.2288140","DOIUrl":"10.1080/14737140.2023.2288140","url":null,"abstract":"Locally advanced and metastatic urothelial carcinoma (UC) presents a bleak prognosis, with limited treatment options. NECTIN-4, an overexpressed protein in UC, has become a target for therapy. Enfortumab vedotin (EV) gained Food and Drug Administration approval for advanced UC treatment, but patient selection based on NECTIN-4 expression remains challenging. In the study under evaluation, Duan et al. introduced a novel PET/CT imaging approach using 68Ga-N188, a molecular probe, to visualize NECTIN-4 expression in UC. Their study encompassed preclinical evaluations and translational assessments in both healthy individuals and UC patients. Results demonstrated the potential of 68Ga-N188 in identifying NECTIN-4 expression in UC lesions. Additionally, the study utilized long axial field-of-view (LAFOV) PET/CT, enhancing sensitivity and enabling dynamic studies for improved radiopharmaceutical evaluation. In summary, the study from Duan and colleagues introduces a promising molecular imaging technique that could aid in patient selection for EV therapy and the development of targeted drugs for UC. It also highlights the potential of LAFOV PET/CT in enhancing imaging precision and expanding future therapeutic possibilities for UC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138294939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations regarding maintenance therapy for acute myeloid leukemia in remission. 缓解期急性髓性白血病维持治疗的注意事项。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-01-01 Epub Date: 2024-02-12 DOI: 10.1080/14737140.2024.2306164

Gary J Schiller, Vlad Kustanovich

{"title":"Considerations regarding maintenance therapy for acute myeloid leukemia in remission.","authors":"Gary J Schiller, Vlad Kustanovich","doi":"10.1080/14737140.2024.2306164","DOIUrl":"10.1080/14737140.2024.2306164","url":null,"abstract":"Introduction: For most adult patients with acute myeloid leukemia, relapse is characteristic of the disease. When allotransplant in first complete remission is administered as consolidative therapy, relapse is still common, affecting 20-40% of recipients. Maintenance of remission with low-dose treatments may hold promise in preventing relapse.Areas covered: Improvements in the detection of clinical and biological variants of disease allow the practitioner to identify which patients, based on disease features, may benefit from therapy directed at residual clonal elements that might contribute to relapse. Along with improvements in methods of detecting residual disease, novel agents are under investigation as a platform in order to maintain remission and may contribute to prolonged survival. In this manuscript, we review literature available through PubMed regarding the use of maintenance therapy, described as post-remission or post-transplant treatment intended to delay or prevent relapse.Expert opinion: Although results of randomized studies are limited, a role for maintenance therapy, particularly directed at molecular targets, in distinct settings of post-remission management is recommended. We also advise that randomized studies of immune therapy along with opportunities for further evaluation of risk-agnostic interventions be a focus of cooperative groups.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer immunotherapy efficacy and machine learning. 癌症免疫疗法疗效与机器学习

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-01-01 Epub Date: 2024-02-12 DOI: 10.1080/14737140.2024.2311684

Yuting Fang, Xiaozhong Chen, Caineng Cao

引用次数: 0

Circadian rhythm-based cancer therapy in randomised clinical trials. 随机临床试验中基于昼夜节律的癌症疗法。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-01-01 Epub Date: 2024-02-12 DOI: 10.1080/14737140.2023.2298835

Loredana G Marcu

{"title":"Circadian rhythm-based cancer therapy in randomised clinical trials.","authors":"Loredana G Marcu","doi":"10.1080/14737140.2023.2298835","DOIUrl":"10.1080/14737140.2023.2298835","url":null,"abstract":"Introduction: Since the 2017 Nobel Prize awarded to J. Hall, M. Rosbash and M.W. Young for their discoveries of molecular mechanisms behind the biological clock, circadian rhythm-based therapy, also known as chronotherapy, is receiving more attention in oncology and the number of anatomical sites of interest in this field is increasing. This observation is in line with the clinical evidence provided by trials on head and neck, lung, colorectal and cervical cancers, as well as the presently ongoing chronotherapy trials for breast and brain cancers.Areas covered: The aim of this review was to collate all randomized trials conducted on chronotherapy for various tumor sites and to appraise the evidence for chrono-oncology to advance personalized therapy. Relevant literature was collected from Pubmed/Medline databases and from clinicatrials.gov.Expert opinion: Current randomized clinical trials offer a certain level of evidence for the potential of chronotherapy to personalize oncologic treatment. However, comparison of trial results is hindered by the differences in timing of radiation/chemotherapy, the absence of harmonized recommendations for treatment outcome evaluation and not ultimately, the general lack of considering gender as a matched variable in trials, which was found to be a powerful factor influencing response to treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0